AOD-9604 does not influence the WADA hGH isoform immunoassay

A key safety concern with any peptide derived from growth hormone is whether it might trigger unwanted growth hormone-related effects in the body. This study by Orlovius, Thomas, Schanzer, and colleagues investigated whether AOD-9604 influences the growth hormone isoform immunoassay used by the World Anti-Doping Agency (WADA), effectively testing whether the peptide cross-reacts with growth hormone pathways.

The researchers tested AOD-9604 against the WADA hGH isoform immunoassay, a sensitive test designed to detect changes in growth hormone profiles. This approach directly assessed whether AOD-9604 administration would alter growth hormone signaling in ways detectable by this standardized assay.

The results confirmed that AOD-9604 does not influence the hGH isoform immunoassay, demonstrating that it operates independently from growth hormone pathways. This independence means that AOD-9604's fat-metabolizing effects are achieved without triggering the broader systemic changes associated with growth hormone administration.

This finding is significant for AOD-9604's safety profile because it provides direct evidence that the peptide targets fat metabolism without activating growth hormone signaling cascades. For patients using AOD-9604 for fat reduction, this confirmed independence from growth hormone pathways supports its favorable safety characteristics.